Choice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trials.

被引：0

作者：

Hansen, Aaron Richard

Cook, Natalie

Ricci, M. Stacey

Razak, Albiruni R. A.

Le Tourneau, Christophe

McKeever, Kathleen

Roskos, Lorin

Dixit, Rakesh

Siu, Lillian L.

Hinrichs, Mary Jane

机构：

[1] Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada

[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[3] US FDA, White Oak, MD USA

[4] Off Oncol & Hematol Prod, Div Hematol & Oncol Toxicol, White Oak, MD USA

[5] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Inst Curie, Dept Med Oncol, Paris, France

[7] MedImmune LLC, Gaithersburg, MD USA

[8] Translat Sci, Gaithersburg, MD USA

[9] MedImmune, Gaithersburg, MD USA

[10] MedImmune, Gaithersburg, MD USA

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2596

引用

页数：1